Top Markets
#1 Black Phoenix Black Phoenix +354.91%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +75.96%
#4 Gold Park Gold Park +62.07%
#5 OpenEden OpenEden +51.46%
#6 Acurast Acurast +32.03%
#7 BasedHype BasedHype +27.15%
#8 Avantis Avantis +21.77%
#9 Cryptopia Cryptopia +21.54%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
Classifica tra le azioni #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Prezzo delle azioni
$0.02653368
Capitalizzazione di mercato
$150.29K
Variazione (1 giorno)
-4.41%
Variazione (1 anno)
194.29%
Paese
GB
Scambia Genflow Biosciences Plc (GENF)

Categoria

Healthcare
Ricavi di Genflow Biosciences Plc (GENF)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Genflow Biosciences Plc, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Genflow Biosciences Plc da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE